BOW 060
Latest Information Update: 14 Jan 2022
At a glance
- Originator EPIRUS Biopharmaceuticals
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; B cell inhibitors; CD20 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer; Inflammation
Most Recent Events
- 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
- 22 May 2015 Discontinued - Preclinical for Cancer in USA (IV)
- 22 May 2015 Discontinued - Preclinical for Inflammation in USA (IV)